A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Ofatumumab (Primary) ; Teriflunomide
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ASCLEPIOS II
- Sponsors Novartis; Novartis Pharmaceuticals
- 27 Jun 2017 Trial desing for two parallel adaptive design studies presented at the 3rd Congress of the European Academy of Neurology
- 28 Apr 2017 Trial design presented at the 69th Annual Meeting of the American Academy of Neurology
- 06 Feb 2017 Planned End Date changed from 1 Jun 2019 to 15 May 2019.